Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
The news archive for Know Labs, Inc. (historically NYSE American: KNW) captures the company’s evolution from a developer of radio frequency dielectric spectroscopy (RFDS) technology for non‑invasive diagnostics to its later transition under the USBC, Inc. name and USBC ticker. Company news releases describe how its RFDS platform directs electromagnetic energy through substances or materials to capture unique molecular signatures, supporting applications such as non‑invasive glucose monitoring and contactless pH measurement.
Readers can review announcements on technology milestones, including laboratory research showing that the company’s RFDS sensor can detect pH changes in real time without direct contact with a liquid, and updates on efforts to advance a non‑invasive blood glucose monitor toward potential FDA clearance. News items also discuss the launch and objectives of Know Labs Technology Licensing (KTL), the division that licenses RFDS technology and the proprietary e‑RFDS© digital watermark to corporations, universities, and research institutions.
The KNW news history further documents significant corporate and capital markets events. These include the 1‑for‑40 reverse stock split effective February 19, 2025, the temporary move to trading on the OTC Pink Market under KNWN while appealing NYSE American delisting proceedings, and subsequent financing and governance developments. Later releases cover the Securities Purchase Agreement with Goldeneye 1995 LLC, the resulting change in control, shareholder approvals to increase authorized common stock and amend the equity incentive plan, and the eventual change of corporate name to USBC, Inc. and trading symbol to USBC.
By browsing this news feed, investors and researchers can trace how Know Labs combined RFDS‑based diagnostic research and licensing with a later strategy that includes a Bitcoin treasury approach and the development of the USBC token, as outlined in joint announcements with Greg Kidd and related SEC filings.
Know Labs, Inc. (NYSE American: KNW) has received a notice of noncompliance with NYSE American continued listing standards. The company fails to meet the stockholders' equity requirements set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. Know Labs must submit a compliance plan by October 27, 2024, outlining how it intends to regain compliance by March 27, 2026.
The notice does not immediately impact the listing of Know Labs' common stock, which will continue to trade under the symbol "KNW" with an added ".BC" designation. The company is preparing its plan based on expected business progress and technological developments, including potential announcements regarding strategic and joint venture partnerships. However, there is no guarantee that Know Labs will achieve compliance within the required timeframe.
Know Labs, Inc. (NYSE American: KNW) announced the publication of its peer-reviewed study in IEEE Sensors Journal, titled 'Non-Invasive Blood Glucose Measurement Using RF Spectroscopy and a lightGBM AI Model'. The study validates the novelty of Know Labs' proprietary radiofrequency (RF) dielectric sensor for non-invasive blood glucose monitoring.
Key points:
- Know Labs' technology uses broadband dielectric spectroscopy, scanning a large range of RF frequencies
- The approach enables the use of thousands of data points for measurement, surpassing traditional resonance techniques
- Results from a first-generation device study were initially announced in May 2023
- Know Labs has since published studies showing improved accuracy in clinical research protocols
- The company is progressing towards FDA clearance with ongoing clinical and bench studies
Know Labs, Inc. (NYSE American: KNW), a developer of non-invasive medical diagnostic technology, has announced a $1.655 million public offering. The company is selling 6,365,385 units at $0.26 per unit, with each unit comprising one common stock share and one warrant to purchase an additional share at $0.26. The offering closed on August 15, 2024.
The net proceeds will be used for product development, clinical studies, general and administrative expenses, intellectual property, and working capital. Boustead Securities, and The Benchmark Company, acted as advisors, receiving a 5% cash fee and warrants for 636,538 common stock shares. The offering is made under Know Labs' effective shelf registration statement on Form S-3.
Know Labs, Inc. (NYSE American: KNW) reported Q3 FY 2024 financial results, showing a net loss of $4.10 million, up 13.9% from Q3 FY 2023. Earnings per share improved to a loss of $0.05 from $0.07 last year. R&D expenses decreased by 28.2% to $1.35 million, while SG&A expenses increased to $2.49 million. The company's cash position decreased to $2.13 million from $8.02 million at the end of FY 2023. Know Labs closed a $3.45 million public offering in August 2024, expecting to fund operations until at least December 31, 2024. The company plans to seek additional funding to ensure operations into 2025 and is taking steps to address negative shareholder equity through debt conversion.
Know Labs (NYSE American: KNW) has successfully closed a $3.445 million public offering of 13,250,000 units at $0.26 per unit. Each unit includes one common stock share and one warrant to purchase an additional share at $0.26. The underwriters partially exercised their option to purchase 1,987,500 warrants. This capital raise is part of Know Labs' strategic plan to accelerate the development of its proprietary technology, including the KnowU™ wearable non-invasive continuous glucose monitoring device. The funds will support ongoing clinical validation studies, product development efforts for FDA clearance, and strengthening the company's intellectual property position.
Know Labs (NYSE American: KNW), a developer of non-invasive medical diagnostic technology, has announced the pricing of a $3.445 million public offering. The offering consists of 13,250,000 units priced at $0.26 per unit, with each unit including one share of common stock and one warrant to purchase an additional share at $0.26. The offering is expected to close around August 9, 2024. Know Labs has granted underwriters a 30-day option to purchase up to 1,987,500 additional shares and/or warrants. The company plans to use the proceeds for product development, clinical studies, general and administrative expenses, intellectual property, and working capital. The Benchmark Company and Boustead Securities are acting as Joint Book-Running Managers for the offering.
Know Labs, Inc. (NYSE American: KNW), a developer of non-invasive medical diagnostic technology, has announced a webcast to review its third quarter fiscal year 2024 results on August 14, 2024, at 1:30 pm PT. The company, which is working on developing the first FDA-cleared non-invasive continuous blood glucose monitoring device, will provide business updates and discuss results for the quarter ended June 30, 2024. Investors and media can access the live audio webcast at a provided link or through the company's investor relations website. A replay of the webcast will also be available on the company's website after the event.
Know Labs announced the publication of its study in the Diabetes Technology & Therapeutics Journal, demonstrating the accuracy of a non-invasive glycemic status screening device. The study showed that their RF dielectric sensor and machine learning algorithms accurately classified glycemic status with 93.37% accuracy compared to venous blood glucose values.
This proof-of-concept device has potential applications for early diabetes diagnosis, especially in underserved global populations. The study involved 31 participants aged 18-65 with prediabetes or Type 2 diabetes, with data collected through an Oral Glucose Tolerance Test and a control session. Results support the efficacy of the RF sensor, though further research is needed to improve sensitivity and specificity, particularly for hypoglycemic states.
Efforts to expand the application beyond proof-of-concept will be led by Chris Somogyi, alongside potential strategic partners, while the company continues to focus on FDA clearance for its non-invasive continuous glucose monitor.
Know Labs (NYSE American: KNW) presented new interim results from a clinical study on its non-invasive radiofrequency (RF) dielectric sensor for blood glucose measurement. The study, involving 22 participants with prediabetes and Type 2 diabetes, showed that the sensor’s accuracy remained statistically stable. Using venous blood as a reference, a new machine learning (ML) model was developed and tested, achieving a Mean Absolute Relative Difference (MARD) of 11.8% ± 1.5%.
Dr. Virend K. Somers from Mayo Clinic, a co-investigator, will present these findings at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida, on June 22, 2024. This study builds on earlier interim results presented at the ATTD conference in March 2024, where the MARD was 11.1%. The current study expanded the dataset from 650 to 1,430 paired RF and reference blood glucose values.
The study used an RF sensor that scans a wide range of frequencies to measure glucose levels, analyzed using ML algorithms. Know Labs plans to continue refining their technology with their newly announced KnowU™ wearable non-invasive continuous glucose monitor in ongoing clinical studies.
Know Labs (NYSE American: KNW) announced its membership in the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Industrial Participant Program (IPP). This collaboration aims to accelerate the development of innovative diagnostic technologies. Know Labs will contribute its expertise in radiofrequency dielectric sensor technology, particularly for non-invasive blood glucose monitoring. The company holds over 300 patents in medical and non-medical applications. Joining the Wyss DxA IPP, Know Labs aims to advance healthcare solutions for diabetes management and general disease prevention. CEO Ron Erickson highlighted the opportunity to contribute to innovation and equitable care.